Annexin A1 (ANXA1
), a 37 kDa monomeric protein, is an endogenous regulator of anti-inflammatory and pro-resolving as well as a mediator of glucocorticoids (GCs) action., A previous study  has shown that ANXA1
could potently downregulate PMN migration into inflammatory sites and accelerate their apoptosis, upregulate the monocytes migration into inflammatory sites.
On performing Gene Set Enrichment Analysis (GSEA), it was found that platelet activation and growth as well as hemostasis were the most significantly enriched gene sets in low BMD condition, while Weighted Gene Coexpression Network Analysis (WGCNA) revealed that Annexin family genes including ANXA1
, ANXA2, ANXA5, and ANXA6 were upregulated in low BMD condition .
In addition, it has been demonstrated that synovial MVs overexpress the anti-inflammatory protein annexin A1 (AnxA1
Genes involved in inflammatory regulation include annexin (ANXA1
)  and S100 calcium binding protein (S100A8, S100A9, and S100P).
Simple diagnostic assay for hairy cell leukemia by immunocytochemical detection of annex A1 (ANXA1
) [published correction appears in Lancet.
Expression of annexin a1 (anxa1
) and a2 (anxa2) and its significance in benign and malignant lesions of gallbladder.
It belongs to the miR-196 precursor family, and miR-196a2 T/C polymorphism (rs11614913) is related to thrombosis and inflammation by regulating annexin A1 (ANXA1
) in the circulation system .
###Specific blood analysis (CEA SCCAA IAP CYFRA ANXA1
The group of upregulated genes combined, among other: insulin-like growth factor 1 (Igf1); insulin induced gene 1 (Insig1); Ccne1; Nek6; fibroblast growth factor 2 (Fgf2); UDP glucuronosyltransferase 1 family, polypeptide A5 (Ugt5a1); annexin 1 (Anxa1
Outstanding among the inflammatory mediators that activate the immune response cascade are the anti-inflammatory proteins annexin-A1 (AnxA1
) and galectin-1 (Gal-1), involved in various inflammatory processes [13,14].
Annexin Al (ANXA1
) has been implicated in the regulation of cell proliferation and apoptosis, and its expression decreases significantly as gastric cancer progresses, which suggests the importance of ANXA1
as a negative biomarker for gastric cancer development (Yu et al., 2008).